Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001279569-18-001180
Filing Date
2018-05-29
Accepted
2018-05-29 14:48:22
Documents
7
Period of Report
2018-05-29

Document Format Files

Seq Description Document Type Size
1 FORM 6-K oncolyticsform6k.htm 6-K 19473
2 NEWS RELEASE DATED MAY 16, 2018 ex991.htm EX-99.1 11155
3 NEWS RELEASE DATED MAY 17, 2018 ex992.htm EX-99.2 11668
4 NEWS RELEASE DATED MAY 22, 2018 ex993.htm EX-99.3 12674
5 NEWS RELEASE DATED MAY 25, 2018 ex994.htm EX-99.4 10458
6 NEWS RELEASE DATED MAY 29, 2018 ex995.htm EX-99.5 7452
7 GRAPHIC image_001.jpg GRAPHIC 9236
  Complete submission text file 0001279569-18-001180.txt   86751
Mailing Address 210 - 1167 KENSINGTON CRES NW CALGARY A0 T2N 1X7
Business Address 1167 KENSINGTON CRES NW SUITE 210 CALGARY ALBERTA CANADA T2N 1X7 ALBERTA CANADA A0 00000 4036707380
ONCOLYTICS BIOTECH INC (Filer) CIK: 0001129928 (see all company filings)

EIN.: 000000000 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 000-31062 | Film No.: 18863950
SIC: 2834 Pharmaceutical Preparations